Neuphoria Provides First Quarter 2025 Business Updates

Core Insights - Neuphoria Therapeutics Inc. is making steady progress in its clinical pipeline, particularly with its lead program BNC210 for Social Anxiety Disorder and partnered asset MK-1167 for Alzheimer's disease [2][6] Clinical Programs - BNC210 is currently enrolling in the AFFIRM-1 Phase 3 study for Social Anxiety Disorder, with topline data expected in Q3 2025 [2][7] - MK-1167 is in a Phase 2 trial led by Merck for Alzheimer's disease, showing continued momentum [2][4] - A Phase 2b trial (SYMPHONY) for BNC210 in PTSD is being planned following a successful End-of-Phase 2 meeting with the FDA [7] Product Details - BNC210 is a first-of-its-kind oral therapy designed to treat social anxiety disorder and PTSD without sedation, cognitive impairment, or addiction potential [4][7] - The drug acts as a selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, aiming to restore neurotransmitter balance [4] Financial Outlook - The company has a cash runway extending into Q3 2026, supporting ongoing clinical trials and development efforts [6]